Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q3 FY2023 Earnings Presentation
16 slides from Aurobindo Pharma's earnings presentation, Feb 9, 2023
Slide 1: Letter to stock exchanges on investor/analyst presentation
February 9, 2023 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Phiroz Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (E), 25th floor, Dalal Street, MUMBAI -400 051 MUMBAI -400 001 Company Code No. AUROPHARMA Company
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q3FY23
Aurobindo Pharma Limited Earnings Presentation Q3FY23
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Table of Content
Table of Content 04 Q3FY23 Business & Financial Highlights 09 Financial Performance 12 Filings Snapshot 3
Slide 5: Q3FY23 Business & Financial Highlights
Q3FY23 Business & Financial Highlights 4
Slide 6: Quarterly Performance – Q3 FY23
Quarterly Performance – Q3 FY23 Revenue (Rs Crore) US Revenue (US$ Mn) 6,500 6,407 500 6,236 401 386 400 367 363 366 5,942 6,002 331 6,000 5,809 5,739 300 200 5,500 100 5,000 0 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q2FY22 Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 EBITDA (Rs Crore) Net Debt to Equity* 1
Slide 7: Consolidated Financial & Business Highlights – Q3 FY23
Consolidated Financial & Business Highlights – Q3 FY23 Revenue from operations at Rs 6,407.1 crore, US revenues at US$ 365.5 Million Research & Development (R&D) spend at Rs 415.2 crore in Q3FY23, 6.5% of revenue Vs. Rs. 275.6 crore in Q2FY23, 4.8% of revenue EBITDA before Forex and Other income at
Slide 8: US Business Performance Highlights
US Business Performance Highlights Revenue (Rs Crore) US Formulations 3,300 3,001 • US revenue in Q3FY23 increased by 9.3% YoY and 13.8% 2,745 2,800 2,638 2,300 QoQ to Rs. 3,001.2 crore, accounting 46.8% of consolidated 1,800 revenue 1,300 800 • Largest generics Company in the US by Rx dispensed^ Q3
Slide 9: Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights
Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights Europe (Rs Crore) Growth Markets (Rs Crore) ARV (Rs Crore) API (Rs Crore) 1,8 00 600 1,010 1,694 1,701 500 1,7 00 499 969 955 450 452 500 1,6 00 1,516 400 1,5 00 397 350 400 1,4 00 251 300 1,3 00 300 250 1,2 00 200 156 164 2
Slide 10: Financial Summary
Financial Summary 9
Slide 11: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) Rs Cr Q3FY23 Q3FY22 YoY Chg. (%) Q2FY23 QoQ Chg. (%) Revenue from operations 6,407.1 6,002.2 6.7 5,739.4 11.6 Gross Profit 3,499.6 3,258.0 7.4 3,171.3 10.4 Gross Margin 54.6% 54.3% -- 55.3% -- Overheads 2,545.2 2,241.7 13.5 2,334.4 9.0 EBITDA (befor
Slide 12: Debt profile
Debt profile Forex Loan (US$ Mn) Debt as on (INR Cr) Mar-20 Mar-21 Mar-22 Sep-22 Dec-22 Closing Rate (INR/USD) 75.665 73.110 75.793 81.345 82.725 732 674 313 277 495 496 Fx Loan restated in INR 5,549 4,929 2,223 3,600 3745.2 Rupee Loan 16.9 43.6 150.1 420.8 355.0 180 110 39 23 36 Gross Debt 5,566 4,
Slide 13: Filing Status
Filing Status 12
Slide 14: US Filings Snapshot as on 31st Dec 2022
US Filings Snapshot as on 31st Dec 2022 ANDA Filings Addressable Market Therapy ANDAs Size (US$ Bn)^ CNS 140 27.8 Aurobindo (Excl. Eugia Pharma Eugia Pharma Specialty Group 600 542 399 143 ARV** 38 0.78 450 160 500 400 140 Specialty Group) 350 120 400 37.0 300 300 250 100 69 CVS 198 187 80 200 200 1
Slide 15: Global regulatory filing Details
Global regulatory filing Details As at As at As at As at As at As at As at As at As at Category Geography Approvals Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Sep 22 Dec 22 US* 398 429 478 541 586 639 727 756 767 (FA: 542, TA:38) Europe** 2,224 2,521 2,848 3,003 3,214 3,374 3,580 3,659 3707 3,
Slide 16: Thank You
Thank You For more information, contact: ir@aurobindo.com Investor Relations | Corporate Communications www.aurobindo.com +91 40 6672 5401 15